Verrica Pharmaceuticals Inc.
VRCA
Rank in Stocks
#21854
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in... Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Share Price
$3.59
Last synced: 2026-11-09
Market Cap
$61.67M
Change (1 day)
12.54%
Change (1 year)
-1.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Verrica Pharmaceuticals Inc. (VRCA)
Category
Healthcare
Operating Margin for Verrica Pharmaceuticals Inc. (VRCA)
Operating Margin as of November 2026 TTM: -92.78%
According to Verrica Pharmaceuticals Inc.'s latest financial reports, its current operating margin (TTM) is -92.78%. At the end of 2025 the company had an operating margin of -33.56%.
Operating Margin history for Verrica Pharmaceuticals Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -92.78% | 176.46% |
| 2025 | -33.56% | -96.15% |
| 2024 | -871.25% | -32.11% |
| 2023 | -1,283.35% | 444.30% |
| 2022 | -235.78% | -8.46% |
| 2021 | -257.57% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.42% |
US
|
|
| -149.01% | -98.39% |
US
|
|
| 25.57% | -100.28% |
AU
|
|
| 31.23% | -100.34% |
BE
|
|
| 29.35% | -100.32% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Verrica Pharmaceuticals Inc.'s operating margin
What is Verrica Pharmaceuticals Inc.'s operating margin?
Verrica Pharmaceuticals Inc.'s operating margin is -92.78%, as of Nov 2026.
What was Verrica Pharmaceuticals Inc.'s operating margin in 2025?
In 2025, Verrica Pharmaceuticals Inc.'s operating margin was -33.56%, compared with -871.25% in 2024.
How has Verrica Pharmaceuticals Inc.'s operating margin changed since 2020?
From 2020 to 2025, Verrica Pharmaceuticals Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2023 (-1,283.35%).
How does Verrica Pharmaceuticals Inc.'s operating margin compare with similar companies?
Verrica Pharmaceuticals Inc.'s operating margin (-92.78%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.